SURGAR
Venture Round in 2024
SURGAR develops a plug-and-play augmented reality software suite for computer-aided laparoscopic surgery. Its software automatically detects tumors and locates critical anatomical structures, enhancing surgical precision.
Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.
Betakorn
Acquisition in 2024
Betakorn is an operator of a holding company that specializes in the management and distribution of collective savings products.
Fasst
Venture Round in 2023
Fasst is involved in the creation, distribution, consulting, and connection of unique digital insurance solutions for brokers and insurers.
i-Virtual
Venture Round in 2023
i-Virtual specializes in advanced sensing technologies, enhancing AI's ability to perceive human vital signs with precision. Its flagship product, Saphere, is a video-based vital sign measurement engine enabling industries like insurance and wellness to harness real-time insights through simple selfies.
Lifesquare
Acquisition in 2023
Lifesquare is a provider of insurance distribution services. They developed a platform that offers loan insurance compatible with all banks, online risk selection, electronic subscription, and personal advice over the phone.
Semeia
Venture Round in 2022
Semeia offers patient monitoring solution designed to support medical followup of patients, remotely and in consultation. They use deep learning technologies to estimate the risk of the occurrence of an adverse event or disruption in the patients care pathway.
FACIL'iti
Venture Round in 2022
FACIL'iti is a digital accessibility platform designed to enhance website usability for individuals with cognitive, motor, and perceptual impairments, as well as senior citizens. The company provides solutions that adapt website displays to meet the specific needs of users without requiring changes to the existing code. This subscription-based service is aimed at web and intranet owners and developers, facilitating a significantly improved and customized browsing experience for individuals facing accessibility challenges. By focusing on the adaptation of digital environments, FACIL'iti addresses the evolving needs of users while promoting inclusivity in the online space.
LegalPlace
Series B in 2022
LegalPlace facilitates business formation and management by providing customizable legal documents and connecting users with experienced lawyers.
Klaro is a French fintech company that operates the first simulator of financial aids in France. Its platform simulates over 1500 national, local, and regional aids to help employees maximize their purchasing power through additional income sources. Klaro aims to combat underutilization of aids by providing a user-friendly platform that guides users through application processes until aid funds are deposited into their bank accounts.
Wandercraft
Series C in 2022
Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.
Xenothera
Series C in 2021
Xenothera is a biotechnology company that specializes in xenotherapy, focusing on the development of innovative immunological treatments. Utilizing a unique technological platform, Xenothera combines expertise in animal genetics with advanced immunology processes to create new therapeutic approaches for various medical conditions, including immunomodulation and infectious diseases. The company is particularly noted for its development of hyperimmune polyclonal sera, which represents a new generation of passive immunotherapy. By controlling the entire process—from the selection of immunogens to the purification of immunoglobulins—Xenothera is able to accelerate the development and market authorization of its therapies, thereby facilitating timely access to novel treatments for patients.
CetteFamille
Series A in 2020
CetteFamille is a French company offering an economical alternative to retirement homes. It connects seniors with professional and accredited host families through its platform, providing a warm, tailored, and cost-effective solution for elderly care.
Squadeasy
Series A in 2019
Squadeasy is a Paris-based company that designs and develops a mobile and web platform aimed at enhancing employee engagement through fitness. The platform facilitates the creation of running competitions among teams, allowing employees to participate regardless of their fitness levels or geographic locations. It promotes physical activity and sustainable mobility in the workplace by offering a gamified workout experience, enabling users to compete in a fun and connected environment. This innovative approach encourages employees to engage in exercise and fosters a sense of community among colleagues.